<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: To examine whether widespread tissue expression of the glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> (GLP)-1 receptor supports the possibility of differential effects of GLP-1-based therapeutics on cardiac function, blood pressure, food intake, gastric emptying, and other regulatory activities </plain></SENT>
<SENT sid="1" pm="."><plain>GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> (RAs) have demonstrated pleiotropic effects on overweight/<z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and cardiovascular (CV) disease </plain></SENT>
<SENT sid="2" pm="."><plain>Food-regulatory effects have been demonstrated in preclinical and clinical trials, including reduced gastric motility and food intake leading to body weight reductions </plain></SENT>
<SENT sid="3" pm="."><plain>Native GLP-1 and GLP-1 RAs have demonstrated cardioprotective effects in preclinical models </plain></SENT>
<SENT sid="4" pm="."><plain>EVIDENCE ACQUISITION: Using PubMed, we performed a search of the recent literature on GLP-1 and GLP-1 RAs </plain></SENT>
<SENT sid="5" pm="."><plain>EVIDENCE SYNTHESIS: Preliminary clinical data indicate native GLP-1 has beneficial effects on endothelial cell function and <z:mp ids='MP_0001863'>vascular inflammation</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Native GLP-1 and GLP-1 RAs have demonstrated renoprotective and <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> effects, and reductions in <z:chebi fb="23" ids="18059">lipid</z:chebi> parameters </plain></SENT>
<SENT sid="7" pm="."><plain>The GLP-1 RA liraglutide has also demonstrated positive effects on such markers of <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-Î± and plasminogen activator inhibitor-1 </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Preliminary data suggest GLP-1 RAs could benefit type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients at risk for CV comorbidities </plain></SENT>
<SENT sid="9" pm="."><plain>Additional studies are needed to confirm the extraglycemic and extrapancreatic effects and determine whether outcomes will translate into beneficial effects for patient care </plain></SENT>
</text></document>